SAB Biotherapeutics reports positive Phase 1 topline results for T1D therapy SAB-142; plans Phase 2b in 2025

SAB Biotherapeutics, Inc.

Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.
SAB-142 showed sustained immunomodulation with MoA analogous to rabbit ATG, correlative to C-peptide preservation.
Company plans to advance SAB-142 into Phase 2b trial in 2025 for adult and pediatric patients with new-onset T1D.
Results presented at R&D webinar on Jan 28, 2025; KOL Michael Haller, MD from Univ of Florida participated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.